SCHEMBL4358434

SCHEMBL4358434

Cc1ccccc1NC(=O)Nc1cc(Cl)ccc1O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNMA1 Q12791 7/20 0.68
CA12 O43570 1/20 0.64
CA1 P00915 1/20 0.64
CA2 P00918 1/20 0.64
CA9 Q16790 1/20 0.64
TRPV1 Q8NER1 1/20 0.63
GRIK1 P39086 1/20 0.59
DDX3X O00571 1/20 0.56
CXCR2 P25025 1/20 0.54
LMNA P02545 2/20 0.53
MAPT P10636 2/20 0.53
MEN1 O00255 1/20 0.53
GAA P10253 1/20 0.53
KMT2A Q03164 1/20 0.53
NTRK1 P04629 1/20 0.53
CDK19 Q9BWU1 1/20 0.53
POLB P06746 3/20 0.53
HTT P42858 2/20 0.52
KDM4E B2RXH2 2/20 0.52
CHRNA7 P36544 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4359936 0.87 KCNMA1 (0.62) KCNMA1CA12CA1CA2CA9
SCHEMBL28295632 0.85 KCNMA1 (0.68) KCNMA1CA12CA1CA2CA9
SCHEMBL7551695 0.85 ALDH1A1 (0.68) KCNMA1LMNAMAPTMEN1GAA
SCHEMBL1883575 0.81 GRIK1 (0.70) KCNMA1CA12CA1CA2CA9
SCHEMBL4349972 0.81 RAB9A (0.66) KCNMA1TRPV1LMNAMAPTMEN1
SCHEMBL4350457 0.81 DDX3X (0.55) CA12CA1CA2CA9TRPV1
SCHEMBL1275926 0.80 RAB9A (0.75) DDX3XMAPTMEN1GAAKMT2A
SCHEMBL4346254 0.79 GRIK1 (0.71) KCNMA1CA12CA1CA2CA9
SCHEMBL4360021 0.79 DDX3X (0.66) CA12CA1CA2CA9TRPV1
SCHEMBL7254163 0.79 KCNMA1 (0.60) KCNMA1GRIK1LMNAMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
CN-100546977-C Suppress the new compound and the application thereof of rotamase JERINI AG (DE) 2009-10-07 CN claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
EP-1402888-A1 The use of substituted carbocyclic compounds as rotamases inhibitors Jerini AG (DE) 2004-03-31 EP claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 KCNMA1 1006/4885CA12 2054/4885CA1 374/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 KCNMA1 1809/4885CA12 2458/4885CA1 532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.